Sterling IMRES
Sign in
Research articleOpen access

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine · 21 November 2019

Read at the publisher
Reference library record. This work was written and published by the people and publisher named here. It is listed in the Sterling IMRES reference library for study and citation. Sterling IMRES did not author or publish it, and listing a work does not mean its authors are affiliated with the institute. Metadata verified via Crossref. How records are verified

Summary

Reports the DAPA-HF trial of dapagliflozin added to standard therapy in patients with heart failure and reduced ejection fraction, with and without diabetes. The trial established SGLT2 inhibition as a treatment for heart failure in its own right and is a cornerstone of current heart-failure care.

Summary written by Sterling IMRES editors. Read the original abstract at the publisher.

Authors

The full author list is available from the publisher.

Cite this work

McMurray JJ, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303

Related publications